Dual Agonism in Action
how GIP and GLP-1 receptor co-activation produces effects greater than either alone
Greater Than the Sum
Tirzepatide's defining innovation is not that it hits GIP or GLP-1 individually -- it is that it hits both simultaneously. The two receptor pathways converge on overlapping metabolic circuits in the pancreas, gut, adipose tissue, and brain, producing synergistic effects that neither pathway achieves alone. This unit maps the points of convergence, explains why dual activation drives greater weight loss and glucose control than selective GLP-1 agonism, and examines the implications for insulin secretion, body composition, and overall metabolic health.
Synergy Dashboard
Visualize how GIP and GLP-1 pathways interact and amplify each other's metabolic effects.